Author’s response to reviews

Title: Cytoreductive Surgery and Hyperthermic Intra-operative Peritoneal Chemotherapy with Cisplatin for Gastric Peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

Authors:

Baki Topal (baki.topal@med.kuleuven.be)
Karel Demey (karel.demey@uzleuven.be)
Halit Topal (halit.topal@uzleuven.be)
Joris Jaekers (joris.jaekers@uzleuven.be)
Eric Van Cutsem (eric.vancutsem@uzleuven.be)
Vincent Vandecaveye (vincent.vandecaveye@uzleuven.be)
Xavier Sagaert (xavier.sagaert@uzleuven.be)
Hans Prenen (hans.prenen@uzleuven.be)

Version: 2 Date: 08 Oct 2017

Author’s response to reviews:

Reviewer/Editor Report & Technical Comments: Q&A

Editor Comments:

Q1. The Group (A vs. B) separation needs clarification in the text and within the figure legend as it remains confusing and unclear. It would be cleaner if defined as group A (PCI \leq 12 with 3 or less non-small bowel regions) and group B (PCI \geq 13 with 4 or more non-small bowel regions) if I am interpreting the intended dichotomy correctly.

A1. Both in in the text and within the figure legend the definition of group A and group B is formulated clearer now.

See Abstract (results & conclusions), Results (in univariable analyses…), Discussion (In patients having PCI …), Conclusion, Figure legends, Table 2.